Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
information fournie par Boursorama CP 02/04/2026 à 17:45

Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.

TG4050 is an individualized immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC’s AI-enabled prediction platform.

.../...

Valeurs associées

TRANSGENE
0,7400 EUR Euronext Paris -3,39%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank